Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder

Carmine Spampanato, Elvira De Leonibus, Paola Dama, Annagiusi Gargiulo, Alessandro Fraldi, Nicolina Cristina Sorrentino, Fabio Russo, Edoardo Nusco, Alberto Auricchio, Enrico M. Surace, Andrea Ballabio

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Multiple sulfatase deficiency (MSD), a severe autosomal recessive disease is caused by mutations in the sulfatase modifying factor 1 gene (Sumf1). We have previously shown that in the Sumf1 knockout mouse model (Sumf1 /) sulfatase activities are completely absent and, similarly to MSD patients, this mouse model displays growth retardation and early mortality. The severity of the phenotype makes MSD unsuitable to be treated by enzyme replacement or bone marrow transplantation, hence the importance of testing the efficacy of novel treatment strategies. Here we show that recombinant adeno-associated virus serotype 9 (rAAV9) vector injected into the cerebral ventricles of neonatal mice resulted in efficient and widespread transduction of the brain parenchyma. In addition, we compared a combined, intracerebral ventricles and systemic, administration of an rAAV9 vector encoding SUMF1 gene to the single administrationseither directly in brain, or systemic alone in MSD mice. The combined treatment resulted in the global activation of sulfatases, near-complete clearance of glycosaminoglycans (GAGs) and decrease of inflammation in both the central nervous system (CNS) and visceral organs. Furthermore, behavioral abilities were improved by the combined treatment. These results underscore that the combined mode of rAAV9 vector administration is an efficient option for the treatment of severe whole-body disorders.

Original languageEnglish
Pages (from-to)860-869
Number of pages10
JournalMolecular Therapy
Volume19
Issue number5
DOIs
Publication statusPublished - May 2011

Fingerprint

Multiple Sulfatase Deficiency Disease
Sulfatases
Dependovirus
Genes
Cerebral Ventricles
Gene Knockout Techniques
Brain
Therapeutics
Glycosaminoglycans
Bone Marrow Transplantation
Knockout Mice
Central Nervous System
Inflammation
Phenotype
Mutation
Mortality
Enzymes
Growth
Serogroup

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Spampanato, C., De Leonibus, E., Dama, P., Gargiulo, A., Fraldi, A., Sorrentino, N. C., ... Ballabio, A. (2011). Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder. Molecular Therapy, 19(5), 860-869. https://doi.org/10.1038/mt.2010.299

Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder. / Spampanato, Carmine; De Leonibus, Elvira; Dama, Paola; Gargiulo, Annagiusi; Fraldi, Alessandro; Sorrentino, Nicolina Cristina; Russo, Fabio; Nusco, Edoardo; Auricchio, Alberto; Surace, Enrico M.; Ballabio, Andrea.

In: Molecular Therapy, Vol. 19, No. 5, 05.2011, p. 860-869.

Research output: Contribution to journalArticle

Spampanato, C, De Leonibus, E, Dama, P, Gargiulo, A, Fraldi, A, Sorrentino, NC, Russo, F, Nusco, E, Auricchio, A, Surace, EM & Ballabio, A 2011, 'Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder', Molecular Therapy, vol. 19, no. 5, pp. 860-869. https://doi.org/10.1038/mt.2010.299
Spampanato, Carmine ; De Leonibus, Elvira ; Dama, Paola ; Gargiulo, Annagiusi ; Fraldi, Alessandro ; Sorrentino, Nicolina Cristina ; Russo, Fabio ; Nusco, Edoardo ; Auricchio, Alberto ; Surace, Enrico M. ; Ballabio, Andrea. / Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder. In: Molecular Therapy. 2011 ; Vol. 19, No. 5. pp. 860-869.
@article{b1e1143ee96a49138fa80c55b4e3da88,
title = "Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder",
abstract = "Multiple sulfatase deficiency (MSD), a severe autosomal recessive disease is caused by mutations in the sulfatase modifying factor 1 gene (Sumf1). We have previously shown that in the Sumf1 knockout mouse model (Sumf1 /) sulfatase activities are completely absent and, similarly to MSD patients, this mouse model displays growth retardation and early mortality. The severity of the phenotype makes MSD unsuitable to be treated by enzyme replacement or bone marrow transplantation, hence the importance of testing the efficacy of novel treatment strategies. Here we show that recombinant adeno-associated virus serotype 9 (rAAV9) vector injected into the cerebral ventricles of neonatal mice resulted in efficient and widespread transduction of the brain parenchyma. In addition, we compared a combined, intracerebral ventricles and systemic, administration of an rAAV9 vector encoding SUMF1 gene to the single administrationseither directly in brain, or systemic alone in MSD mice. The combined treatment resulted in the global activation of sulfatases, near-complete clearance of glycosaminoglycans (GAGs) and decrease of inflammation in both the central nervous system (CNS) and visceral organs. Furthermore, behavioral abilities were improved by the combined treatment. These results underscore that the combined mode of rAAV9 vector administration is an efficient option for the treatment of severe whole-body disorders.",
author = "Carmine Spampanato and {De Leonibus}, Elvira and Paola Dama and Annagiusi Gargiulo and Alessandro Fraldi and Sorrentino, {Nicolina Cristina} and Fabio Russo and Edoardo Nusco and Alberto Auricchio and Surace, {Enrico M.} and Andrea Ballabio",
year = "2011",
month = "5",
doi = "10.1038/mt.2010.299",
language = "English",
volume = "19",
pages = "860--869",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder

AU - Spampanato, Carmine

AU - De Leonibus, Elvira

AU - Dama, Paola

AU - Gargiulo, Annagiusi

AU - Fraldi, Alessandro

AU - Sorrentino, Nicolina Cristina

AU - Russo, Fabio

AU - Nusco, Edoardo

AU - Auricchio, Alberto

AU - Surace, Enrico M.

AU - Ballabio, Andrea

PY - 2011/5

Y1 - 2011/5

N2 - Multiple sulfatase deficiency (MSD), a severe autosomal recessive disease is caused by mutations in the sulfatase modifying factor 1 gene (Sumf1). We have previously shown that in the Sumf1 knockout mouse model (Sumf1 /) sulfatase activities are completely absent and, similarly to MSD patients, this mouse model displays growth retardation and early mortality. The severity of the phenotype makes MSD unsuitable to be treated by enzyme replacement or bone marrow transplantation, hence the importance of testing the efficacy of novel treatment strategies. Here we show that recombinant adeno-associated virus serotype 9 (rAAV9) vector injected into the cerebral ventricles of neonatal mice resulted in efficient and widespread transduction of the brain parenchyma. In addition, we compared a combined, intracerebral ventricles and systemic, administration of an rAAV9 vector encoding SUMF1 gene to the single administrationseither directly in brain, or systemic alone in MSD mice. The combined treatment resulted in the global activation of sulfatases, near-complete clearance of glycosaminoglycans (GAGs) and decrease of inflammation in both the central nervous system (CNS) and visceral organs. Furthermore, behavioral abilities were improved by the combined treatment. These results underscore that the combined mode of rAAV9 vector administration is an efficient option for the treatment of severe whole-body disorders.

AB - Multiple sulfatase deficiency (MSD), a severe autosomal recessive disease is caused by mutations in the sulfatase modifying factor 1 gene (Sumf1). We have previously shown that in the Sumf1 knockout mouse model (Sumf1 /) sulfatase activities are completely absent and, similarly to MSD patients, this mouse model displays growth retardation and early mortality. The severity of the phenotype makes MSD unsuitable to be treated by enzyme replacement or bone marrow transplantation, hence the importance of testing the efficacy of novel treatment strategies. Here we show that recombinant adeno-associated virus serotype 9 (rAAV9) vector injected into the cerebral ventricles of neonatal mice resulted in efficient and widespread transduction of the brain parenchyma. In addition, we compared a combined, intracerebral ventricles and systemic, administration of an rAAV9 vector encoding SUMF1 gene to the single administrationseither directly in brain, or systemic alone in MSD mice. The combined treatment resulted in the global activation of sulfatases, near-complete clearance of glycosaminoglycans (GAGs) and decrease of inflammation in both the central nervous system (CNS) and visceral organs. Furthermore, behavioral abilities were improved by the combined treatment. These results underscore that the combined mode of rAAV9 vector administration is an efficient option for the treatment of severe whole-body disorders.

UR - http://www.scopus.com/inward/record.url?scp=79955574241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955574241&partnerID=8YFLogxK

U2 - 10.1038/mt.2010.299

DO - 10.1038/mt.2010.299

M3 - Article

C2 - 21326216

AN - SCOPUS:79955574241

VL - 19

SP - 860

EP - 869

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -